Study of YK012 in B-cell Acute Lymphoblastic Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
DRUG

YK012

The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.

Trial Locations (12)

110000

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

116001

RECRUITING

Affiliated Zhongshan Hospital of Dalian University, Dalian

130021

RECRUITING

The First Hospital of Jilin University, Changchun

221000

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

330006

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

450003

RECRUITING

Henan Provincial People's Hospital, Zhengzhou

510000

RECRUITING

Sun Yat-sen Memorial Hospital, Guangzhou

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

510080

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

550004

RECRUITING

The Affiliated Hospital of Guizhou Medical University, Guiyang

650033

RECRUITING

The Second Affiliated Hospital of Kunming Medical University, Kunming

Sponsors
All Listed Sponsors
lead

Excyte Biopharma Ltd

INDUSTRY